Positioning Antiverse as a Leader in AI Drug Discovery

Antiverse is an AI-driven techbio company that designs antibodies against some of biology's most difficult targets, including G-protein coupled receptors and ion channels. Headquartered in Cardiff with offices in Boston and Prague, it combines machine learning with advanced cell line engineering to develop de novo antibody therapeutics. Antiverse brought SomX in to sharpen its brand and positioning as it prepared for a Series A raise and set out to build new pharma partnerships.
Client
Antiverse
Category
Public Relations, Marketing, Design
Services
Media Relations, Thought Leadership, Content, Deck Design
Positioning Antiverse as a Leader in AI Drug Discovery

Solution

Antiverse had strong technical foundations, rich scientific data and growing commercial traction, but its communications needed to keep pace with a fast-moving AI drug discovery market. The company wanted to be understood clearly as a techbio business, articulate its differentiators to investors, and hold a consistent brand across its investor and partnership materials.

A multi-channel communications strategy

We built and ran a programme across content, PR and design to grow awareness of Antiverse's platform and technology among investor and biotech audiences.

Media and partnership announcements

We worked closely with Antiverse's partners to shape and amplify partnership announcements, and crafted narratives that put the company's technology and founder credentials in front of the right readers.

Investor and partnership collateral

We redesigned and re-edited Antiverse's investor and partnership decks so they conveyed the company's differentiators clearly and stayed consistent with the wider brand.

Results

  • More than 40 pieces of coverage across national, trade and international media: Antiverse featured in titles including The Times, Associated Press, Axios, Drug Discovery World, BioSpace and Pharmaphorum, with international pickup taking its story well beyond the sector press.
  • A flagship partnership amplified: we led communications on Antiverse's partnership with Nxera Pharma, securing coverage in The Times and Sifted and framing it as a signal of momentum in AI drug discovery.
  • Positioned as a serious scientific voice: thought leadership in GEN, Drug Target Review, Manufacturing Chemist and Drug Discovery World established Antiverse's team as authorities on antibody design and AI-led discovery.
  • A raised founder and company profile: founder interviews and features, including with NASDAQ and Forbes journalists, lifted Antiverse's standing with investors and partners.
  • An investor-ready brand: a redesigned investor and partnerships deck that conveys the company's USPs with a consistent look across materials.

Reflection

Antiverse is doing genuinely hard science, and the job was to make that legible to investors and partners without flattening the detail. We held the technical credibility while sharpening the story, then made sure the brand and the decks matched the ambition behind it. Heading into its Series A and a new wave of partnership conversations, Antiverse now reads clearly as one of the techbio companies to watch in AI antibody design.

Other Projects

Medosync
Pfizer
MORE WORK